Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection
Latest Information Update: 08 Mar 2022
At a glance
- Drugs Atovaquone (Primary) ; Azithromycin (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 17 Feb 2022 Status changed from recruiting to discontinued.
- 01 Dec 2020 Planned End Date changed from 1 Apr 2021 to 1 Dec 2021.
- 01 Dec 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Jul 2021.